Products - Peritoneal cancer | Topic | NICE

Showing 10 products

Date | Title

Status: PublishedRemove ‘Status: Published’ filter

Niraparib for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy (TA1129)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
12 February 2026
Rucaparib for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy (TA1055)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
16 April 2025
Rucaparib for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer (TA1007)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
17 September 2024
Olaparib for maintenance treatment of BRCA mutation-positive advanced ovarian, fallopian tube or peritoneal cancer after response to first-line platinum-based chemotherapy (TA962)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
28 March 2024
Olaparib with bevacizumab for maintenance treatment of advanced high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer (TA946)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
17 January 2024
Olaparib for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube or peritoneal cancer after 2 or more courses of platinum-based chemotherapy (TA908)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
5 July 2023
Niraparib for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer (TA784)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
20 April 2022
Cytoreduction surgery with hyperthermic intraoperative peritoneal chemotherapy for peritoneal carcinomatosis (HTG569)
Product type:
Guidance
Programme:
HealthTech guidance
Published:
3 March 2021
Pressurised intraperitoneal aerosol chemotherapy for peritoneal carcinomatosis (HTG558)
Product type:
Guidance
Programme:
HealthTech guidance
Published:
28 October 2020
Bevacizumab for treating relapsed, platinum‑resistant epithelial ovarian, fallopian tube or primary peritoneal cancer (terminated appraisal) (TA353)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
26 August 2015